Moderna, Inc. (NASDAQ:MRNA) | Finanzwire

Basculer en Français

10051	Companies
205085	Keywords
135325	Articles
108731	Press releases

Home
Companies
Moderna, Inc.

PRESS RELEASE

published on 06/06/2024 at 13:00, 1 year 9 months ago

Moderna's Investigational Therapeutic for Methylmalonic Acidemia (mRNA-3705) Selected by U.S. Food & Drug Administration for START Pilot Program
Moderna's mRNA-3705 selected for FDA's START pilot program to address rare diseases. The investigational mRNA therapeutic aims to treat methylmalonic acidemia due to MUT deficiency with innovative mRNA platform

Moderna Rare Diseases MMA MRNA-3705 START Pilot Program
PRESS RELEASE

published on 06/03/2024 at 14:00, 1 year 9 months ago

Moderna & Merck Announce 3-Year Data For mRNA-4157 (V940) in Combination With KEYTRUDA(R) (pembrolizumab) Demonstrated Sustained Improvement in Recurrence-Free Survival & Distant Metastasis-Free Survival Versus KEYTRUDA in Patients With High-Risk Stage II
BRIEF

published on 05/31/2024 at 17:03, 1 year 9 months ago

Moderna Receives U.S. FDA Approval for RSV Vaccine mRESVIA

FDA Approval Moderna Vaccine RSV MRESVIA
PRESS RELEASE

published on 05/31/2024 at 16:58, 1 year 9 months ago

Moderna Receives U.S. FDA Approval for RSV Vaccine mRESVIA(R)
Moderna gains FDA approval for mRESVIA, a single-dose pre-filled syringe RSV vaccine for adults 60+ to prevent lower respiratory tract disease. Second mRNA product and breakthrough therapy designation

FDA Approval Moderna RSV Vaccine MRNA MRESVIA
BRIEF

published on 05/22/2024 at 13:05, 1 year 9 months ago

Moderna Announces Data to be Presented at 2024 ASCO Annual Meeting

Clinical Trials Immunotherapy Moderna ASCO 2024 MRNA-4157
PRESS RELEASE

published on 05/22/2024 at 13:00, 1 year 9 months ago

Moderna Announces Data to be Presented at 2024 ASCO Annual Meeting
Moderna to host an investor event via webcast on June 3 at 6:15 PM CDT. Abstracts on mRNA-4157 for ASCO Annual Meeting. Details on mRNA-4157 (V940) therapy development

Webcast Moderna Investor Event MRNA-4157 Neoantigen Therapy
BRIEF

published on 05/13/2024 at 13:05, 1 year 10 months ago

Moderna Announces Participation in Key Investor Conferences

Investor Conferences Healthcare Financial Markets Moderna Webcasts
PRESS RELEASE

published on 05/13/2024 at 13:00, 1 year 10 months ago

Moderna to Present at Upcoming Conferences in May/June 2024
Moderna, Inc. to participate in upcoming investor conferences, showcasing its leadership in mRNA medicine and innovative approach to disease treatment. Live webcasts available

Investor Conferences Moderna Inc. MRNA Medicine Webcasts Disease Treatment
BRIEF

published on 05/02/2024 at 12:35, 1 year 10 months ago

Moderna Reports Q1 2024 Financial Performance and Strategic Progress

Financial Results MRNA Technology Moderna RSV Vaccine Vaccine Development
PRESS RELEASE

published on 05/02/2024 at 12:30, 1 year 10 months ago

Moderna Reports First Quarter 2024 Financial Results and Provides Business Updates
Moderna, Inc. reports Q1 revenues of $167 million, GAAP net loss of $1.2 billion, and diluted EPS of $(3.07). Company prepares for RSV vaccine and Spikevax® 2024-2025 formula launches, with expected product sales of $4 billion in 2024

Moderna Inc. Net Loss RSV Vaccine Q1 Revenues Spikevax 2024-2025 Formula

Accesswire

Published on 03/19/2026 at 01:05, 3 hours 4 minutes ago

Prospect Ridge Announces Closing of Flow-Through Share Private Placement
Published on 03/18/2026 at 23:45, 4 hours 24 minutes ago

Orogen Royalties Announces Private Placement Update
Published on 03/18/2026 at 21:00, 7 hours 9 minutes ago

PLDT's Smart Selects Amdocs to Transform Retail Operations with AI-Powered Store Genie
Published on 03/18/2026 at 19:05, 9 hours 4 minutes ago

Deposit Modeling at Thor Shows that the Proven Thor Epithermal Deposit is Flanked on Both Sides by a Much Larger Deposit
Published on 03/18/2026 at 18:10, 9 hours 59 minutes ago

Silver X Mining Closes C$69M Brokered Private Placement of Secured Convertible Debentures

View all ACCESSWIRE

EQS Group

Published on 03/19/2026 at 03:50, 19 minutes ago

AWE2026 Signals the Future: A Defining Moment for the Age of AI
Published on 03/18/2026 at 22:00, 6 hours 9 minutes ago

aap successfully completes MDR certification: All existing products approved according to MDR – market access in the EU and CE-relevant markets secured in the long term
Published on 03/18/2026 at 18:53, 9 hours 16 minutes ago

EQS-Adhoc: Formycon AG postpones the publication of its audited annual and consolidated financial statements for 2025
Published on 03/18/2026 at 18:37, 9 hours 32 minutes ago

Fuller, Smith & Turner PLC: Transaction in own shares
Published on 03/18/2026 at 18:27, 9 hours 42 minutes ago

POS-Transaction in Own Shares

Les Echos

Published on 03/18/2026 at 19:41, 8 hours 27 minutes ago

Covivio - Conditions of availability of the 2025 Universal Registration Document
Published on 03/18/2026 at 18:00, 10 hours 9 minutes ago

Deezer achieves profitability in FY25 as strategy delivers tangible results
Published on 03/18/2026 at 17:45, 10 hours 24 minutes ago

Infotel : 2025 full-year results. Launch of a new Infotel 2030 strategic plan. Revenue target of €500 million by 2030.
Published on 03/18/2026 at 17:40, 10 hours 29 minutes ago

260318 BENETEAU Presentation FY 2025
Published on 03/18/2026 at 17:40, 10 hours 29 minutes ago

260318 BENETEAU FY 2025 Results

View all LES ECHOS COMFI WIRE